Human medicines European public assessment report (EPAR): Votubia, everolimus, Date of authorisation: 02/09/2011, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Votubia, everolimus, Date of authorisation: 02/09/2011, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Esmya, ulipristal, Date of authorisation: 22/02/2012, Revision: 16, Status: Withdrawn

Human medicines European public assessment report (EPAR): Esmya, ulipristal, Date of authorisation: 22/02/2012, Revision: 16, Status: Withdrawn

Human medicines European public assessment report (EPAR): Raxone, idebenone, Date of authorisation: 08/09/2015, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Raxone, idebenone, Date of authorisation: 08/09/2015, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Tecartus, brexucabtagene autoleucel, Date of authorisation: 14/12/2020, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Tecartus, brexucabtagene autoleucel, Date of authorisation: 14/12/2020, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Yescarta, axicabtagene ciloleucel, Date of authorisation: 23/08/2018, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Yescarta, axicabtagene ciloleucel, Date of authorisation: 23/08/2018, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Qaialdo, spironolactone, Date of authorisation: 26/05/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Qaialdo, spironolactone, Date of authorisation: 26/05/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 8, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness